Editas Medicine, Inc.

Healthcare

NASDAQ:EDIT · NASDAQ Global Select

Market Cap $244.75M Beta 2.10 P/E (TTM) -2.2

$2.50 +2.46%

+$0.06 today

52W Low $1.66High $4.54

Vol 1.90M · Avg 2.00M

EPS (TTM)-$1.11

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+26.90%

Period High

$4.15

Period Low

$1.67

Latest

$2.50

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Capricor Therapeutics, Inc.

NASDAQ:CAPR

$1.18B

Cabaletta Bio, Inc.

NASDAQ:CABA

$490.79M

Allogene Therapeutics, Inc.

NASDAQ:ALLO

$463.35M

Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

$359.32M

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

$353.00M

Kyverna Therapeutics, Inc.

NASDAQ:KYTX

$352.74M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

$315.01M

Voyager Therapeutics, Inc.

NASDAQ:VYGR

$211.47M

ProQR Therapeutics N.V.

NASDAQ:PRQR

$151.72M

Immutep Limited

NASDAQ:IMMP

$53.60M

What is the latest EDIT filing?

The latest filing shown is 4 dated Jun 5, 2026.

How many recent filings does EDIT have?

Intrinsic Alpha currently shows 20 recent filings for EDIT.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.